4.8 Article

Multiyear Factor VIII Expression after AAV Gene Transfer for Hemophilia A

相关参考文献

注意:仅列出部分参考文献,下载原文获取全部文献信息。
Article Hematology

BAX 335 hemophilia B gene therapy clinical trial results: potential impact of CpG sequences on gene expression

Barbara A. Konkle et al.

Summary: Gene therapy has the potential to maintain therapeutic blood clotting factor IX levels in patients with hemophilia B. This study investigated the use of a gene therapy, BAX 335, in hemophilia B patients, showing promising results in maintaining FIX activity.
Article Hematology

Partial F8 gene duplication (factor VIII Padua) associated with high factor VIII levels and familial thrombophilia

Paolo Simioni et al.

Summary: This study identified the molecular basis of high FVIII levels leading to severe thrombophilia in two Italian families, involving a tandem duplication of the proximal portion of the F8 gene. This rearrangement led to upregulation of F8 messenger RNA and transcriptional enhancement, potentially mediating the severe thrombophilia observed in carriers of the duplication.
Article Hematology

Activated protein C has a regulatory role in factor VIII function

Amelia R. Wilhelm et al.

Summary: This study compared an APC-resistant FVIII variant with wild-type FVIII, and found that APC plays an important role in the in vivo regulation of FVIIIa, which could be exploited for developing novel treatments for hemophilia A.
Article Biotechnology & Applied Microbiology

A long-term study of AAV gene therapy in dogs with hemophilia A identifies clonal expansions of transduced liver cells

Giang N. Nguyen et al.

Summary: Nine dogs with hemophilia A were treated with AAV gene therapy expressing canine factor VIII and followed for up to 10 years. The therapy corrected the FVIII deficiency in most dogs, with some showing gradual increase in FVIII activity possibly due to clonal expansion of cells. Long-term monitoring for potential genotoxicity is essential for the clinical development of liver-directed AAV gene therapy for hemophilia A.

NATURE BIOTECHNOLOGY (2021)

Article Cell Biology

Engineering adeno-associated viral vectors to evade innate immune and inflammatory responses

Ying Kai Chan et al.

Summary: The study engineered AAV vectors by incorporating short DNA oligonucleotides to antagonize TLR9 activation, reducing innate immune responses and enhancing gene expression in clinically relevant animal models. The engineered vectors can avoid adverse reactions in some models, demonstrating a potential wider therapeutic window for AAV therapies.

SCIENCE TRANSLATIONAL MEDICINE (2021)

Article Medicine, General & Internal

Multiyear Follow-up of AAV5-hFVIII-SQ Gene Therapy for Hemophilia A

K. John Pasi et al.

NEW ENGLAND JOURNAL OF MEDICINE (2020)

Review Medicine, Research & Experimental

Protein-Engineered Coagulation Factors for Hemophilia Gene Therapy

Benjamin J. Samelson-Jones et al.

MOLECULAR THERAPY-METHODS & CLINICAL DEVELOPMENT (2019)

Article Medicine, General & Internal

Emicizumab Prophylaxis in Patients Who Have Hemophilia A without Inhibitors

J. Mahlangu et al.

NEW ENGLAND JOURNAL OF MEDICINE (2018)

Article Medicine, General & Internal

Hemophilia B Gene Therapy with a High-Specific-Activity Factor IX Variant

L. A. George et al.

NEW ENGLAND JOURNAL OF MEDICINE (2017)

Article Medicine, General & Internal

AAV5-Factor VIII Gene Transfer in Severe Hemophilia A

Savita Rangarajan et al.

NEW ENGLAND JOURNAL OF MEDICINE (2017)

Article Medicine, Research & Experimental

Overexpression of factor VIII after AAV delivery is transiently associated with cellular stress in hemophilia A mice

Amy M. Lange et al.

MOLECULAR THERAPY-METHODS & CLINICAL DEVELOPMENT (2016)

Article Medicine, Research & Experimental

Potential for cellular stress response to hepatic factor VIII expression from AAV vector

Irene Zolotukhin et al.

MOLECULAR THERAPY-METHODS & CLINICAL DEVELOPMENT (2016)

Article Medicine, Research & Experimental

Vector design influences hepatic genotoxicity after adeno-associated virus gene therapy

Randy J. Chandler et al.

JOURNAL OF CLINICAL INVESTIGATION (2015)

Article Hematology

Murine coagulation factor VIII is synthesized in endothelial cells

Lesley A. Everett et al.

Article Multidisciplinary Sciences

Selection and evaluation of clinically relevant AAV variants in a xenograft liver model

Leszek Lisowski et al.

NATURE (2014)

Article Medicine, General & Internal

Long-Term Safety and Efficacy of Factor IX Gene Therapy in Hemophilia B

A. C. Nathwani et al.

NEW ENGLAND JOURNAL OF MEDICINE (2014)

Article Biochemistry & Molecular Biology

Enhanced Biosynthesis of Coagulation Factor VIII through Diminished Engagement of the Unfolded Protein Response

Harrison C. Brown et al.

JOURNAL OF BIOLOGICAL CHEMISTRY (2011)

Article Medicine, General & Internal

Adenovirus-Associated Virus Vector-Mediated Gene Transfer in Hemophilia B

Amit C. Nathwani et al.

NEW ENGLAND JOURNAL OF MEDICINE (2011)

Review Multidisciplinary Sciences

The Unfolded Protein Response: From Stress Pathway to Homeostatic Regulation

Peter Walter et al.

SCIENCE (2011)

Article Multidisciplinary Sciences

Antioxidants reduce endoplasmic reticulum stress and improve protein secretion

Jyoti D. Malhotra et al.

PROCEEDINGS OF THE NATIONAL ACADEMY OF SCIENCES OF THE UNITED STATES OF AMERICA (2008)

Article Medicine, General & Internal

Prophylaxis versus episodic treatment to prevent joint disease in boys with severe hemophilia

Marilyn J. Manco-Johnson et al.

NEW ENGLAND JOURNAL OF MEDICINE (2007)

Article Multidisciplinary Sciences

AAV vector integration sites in mouse hepatocellular carcinoma

Anthony Donsante et al.

SCIENCE (2007)

Article Biochemistry & Molecular Biology

CD8+ T-cell responses to adeno-associated virus capsid in humans

Federico Mingozzi et al.

NATURE MEDICINE (2007)

Review Medicine, General & Internal

Medical progress - The hemophilias - From royal genes to gene therapy

PM Mannucci et al.

NEW ENGLAND JOURNAL OF MEDICINE (2001)